Premature mortality in epilepsy and the role of psychiatric comorbidity: a total population study  by Fazel, Seena et al.
Articles
1646 www.thelancet.com   Vol 382   November 16, 2013
Premature mortality in epilepsy and the role of psychiatric 
comorbidity: a total population study 
Seena Fazel, Achim Wolf, Niklas Långström, Charles R Newton, Paul Lichtenstein 
Summary
Background Epilepsy is associated with high rates of premature mortality, but the contribution of psychiatric comorbidity 
is uncertain. We assessed the prevalence and risks of premature mortality from external causes such as suicide, accidents, 
and assaults in people with epilepsy with and without psychiatric comorbidity. 
Methods We studied all individuals born in Sweden between 1954 and 2009 with inpatient and outpatient diagnoses 
of epilepsy (n=69 995) for risks and causes of premature mortality. Patients were compared with age-matched and 
sex-matched general population controls (n=660 869) and unaﬀ ected siblings (n=81 396). Sensitivity analyses were 
done to investigate whether these odds diﬀ ered by sex, age, seizure types, comorbid psychiatric diagnosis, and 
diﬀ erent time periods after epilepsy diagnosis.
Findings 6155 (8.8%) people with epilepsy died during follow-up, at a median age of 34·5 (IQR 21·0–44·0) years with 
substantially elevated odds of premature mortality (adjusted odds ratio [aOR] of 11·1 [95% CI 10·6–11·6] compared 
with general population controls, and 11·4 [10·4–12·5] compared with unaﬀ ected siblings). Of those deaths, 15·8% 
(n=972) were from external causes, with high odds for non-vehicle accidents (aOR 5·5, 95 % CI 4·7–6·5) and suicide 
(3·7, 3·3–4·2). Of those who died from external causes, 75·2% had comorbid psychiatric disorders, with strong 
associations in individuals with co-occurring depression (13·0, 10·3–16·6) and substance misuse (22·4, 18·3–27·3), 
compared with patients with no epilepsy and no psychiatric comorbidity. 
Interpretation Reducing premature mortality from external causes of death should be a priority in epilepsy 
management. Psychiatric comorbidity plays an important part in the premature mortality seen in epilepsy. The ability 
of health services and public health measures to prevent such deaths requires review.
Funding Wellcome Trust, the Swedish Prison and Probation Service, and the Swedish Research Council. 
Introduction
Epilepsy accounts for an estimated 0·7% of the global 
burden of disease.1 It aﬀ ects around 70 million people,2 
and contributes to over 17 million disability-adjusted 
life-years annually.1 Premature mortality is substantial3 
and almost half of epilepsy-related deaths occur in those 
younger than 55 years, corresponding to standardised 
mortality ratios above 10 for hospitalised patients.4 
Suicide is associated with up to 5% of all epilepsy 
deaths,5 but whether epilepsy is independently associated 
with suicide is unclear. One study suggested that epilepsy 
is an independent risk factor for suicide after controlling 
for psychiatric comorbidity,6 but studies from Canada7 and 
the UK8 reported no independent relation. There have also 
been conﬂ icting conclusions about whether epilepsy is a 
risk factor for suicide when psychiatric comorbidity is not 
present.6,7 Clariﬁ cation would assist national suicide pre-
vention strategies that increasingly focus on high-risk 
populations,9,10 particularly if such groups can be identi-
ﬁ ed, and could also inform treatment guidelines. 
Other major causes of epilepsy-related deaths are 
vehicle and non-vehicle accidents,10,11 which contribute to 
up to 16% of deaths.12 Restrictions for drivers with epilepsy 
have probably contributed to death rates from motor 
vehicle accidents not being signiﬁ cantly higher than that 
of the general population in certain countries.7 However, 
the role of public health and education measures in 
reducing mortality from non-vehicle accidents in patients 
with epilepsy is uncertain. In particular, possible asso-
ciations of non-vehicle accidental deaths with psychiatric 
disorders need clariﬁ cation, and previous studies have 
not investigated psychiatric comorbidity.11 
In our 41-year population study of 69 995 individuals 
with epilepsy, we aimed to investigate prevalence and 
risks of premature mortality, and to address two speciﬁ c 
issues. First, whether epilepsy is independently asso-
ciated with external causes of death. To clarify this, we 
compared people with epilepsy with the general 
population and unaﬀ ected sibling controls. If there is a 
link between epilepsy and death from external causes, 
the use of sibling controls enables clariﬁ cation of whether 
this association is consistent with a causal hypothesis or 
due to residual confounding, including genetic and early 
environmental factors. Second, we investigated the 
association of epilepsy with premature mortality in 
patients with and without comorbid psychiatric disorders. 
Methods
Study setting
We linked several longitudinal, nationwide population 
registers in Sweden: the Patient Register (held at the 
National Board of Health and Welfare), the Censuses 
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from 1970 and 1990 (Statistics Sweden), the Multi-
Generation Register (Statistics Sweden), and the 
Cause-of-Death Register (National Board of Health and 
Welfare). The Multi-Generation Register connects every 
person born in Sweden from 1933 onwards and ever 
registered as living in Sweden after 1960 to their 
parents.13 For immigrants, similar information exists 
for those who became citizens of Sweden before aged 
18 years, together with one or both parents. In Sweden, 
all residents including immigrants have a unique 
ten-digit personal identiﬁ cation number that is used in 
all national registers, thus making the linking of data 
possible. We selected a cohort of people born between 
1954 and 2009, and followed them up for up to 41 years, 
from 1969 to the end of follow-up in 2009 (n=7 238 800). 
The Patient Registers started in 1969; hence we began 
our follow-up at that point, which meant that children 
diagnosed with epilepsy who died between 1954 and 
1968 were not included in the cohort. A sensitivity 
analysis addressed whether this aﬀ ected the main 
ﬁ ndings. Using the Multi-Generation Register, we also 
identiﬁ ed patients with epilepsy who had full siblings 
without epilepsy. 
The Regional Ethics Committee at Karolinska Institutet 
approved the study (2009/939-31/5). Data were merged 
and anonymised by an independent government agency 
(Statistics Sweden), and the code linking the personal 
identiﬁ cation numbers to the new case numbers was 
destroyed immediately after merging. Therefore, in-
formed consent was not required.
Measures
Epilepsy
Epilepsy was identiﬁ ed through the National Patient 
Register, which includes individuals hospitalised 
(starting in 1969 but with total national coverage 
from 1987) or having outpatient appointments with 
specialist physicians (since 2001) in Sweden.14 
Patients with epilepsy had to have had at least one 
episode in which the diagnosis was made according to 
the International Classiﬁ cation of Diseases (ICD) ICD-8 
(1969–1986; diagnostic codes 345.00–345.99), ICD-9 
(1987–1996; codes 345J, K, L, M, N, P, Q, W, X), or ICD-10 
(from 1997 onwards; codes G40.1–G40.9, G41). 
Diagnostic validity
Swedish patient register data for diagnoses have good to 
excellent validity for a range of disorders, including 
neurological conditions such as acute stroke15 and 
Guillain-Barré syndrome,16 and psychiatric illnesses 
such as bipolar disorder17 and schizophrenia.18 Overall, 
the positive predictive value of the inpatient register, in 
a recent review, was found to be 85–95% for most 
diagnoses.19 Less is known about comorbidity, although 
one study found fair to moderate agreement for 
comorbid substance misuse in schizophrenia (κ=0·37, 
standard error 0·23, p<0·001, corresponding to 68% 
full agree ment).20 Since only around 1% of hospital 
admissions have missing personal identiﬁ cation 
numbers,21 the register has been used in various 
epidemiological investigations.22,23
Outcome measures
Data for causes of death were retrieved for all individuals 
who died between 1969 and 2009. The Cause of Death 
register, based on death certiﬁ cates, covers over 99% of 
all deaths.24 We extracted both all-cause mortality data 
and separately by ICD chapter, including external causes. 
Within external causes, we further examined deaths by 
suicide, vehicle and non-vehicle accidents, and assault. 
In line with previous work,25 undetermined deaths (ICD 
codes Y10-Y34) were included as suicides since their 
exclusion would underestimate actual rates.26
Sociodemographic and psychiatric covariates
Mean lifetime disposable income (divided into thirds) 
was used as a proxy for income, and used as a dichoto-
mous variable (lowest tertile vs top two tertiles). If this 
information was unavailable, family lifetime disposable 
income, or parents’ lifetime disposable income was used 
instead and similarly divided into tertiles. Single mari-
tal status was deﬁ ned as being unmarried at end of 
Patients with epilepsy 
(n=69 995)
General population 
controls
(n=660 869)
Patients with 
epilepsy with 
unaﬀ ected siblings 
(n=48 437)
Unaﬀ ected sibling 
controls
(n=81 396)
Male, n (%) 36 999 (52·9%) 348 561 (52·7%) 22 751 (53·0%) 41 786 (51·3%)
Single status, n (%) 50 099 (71·6%) 417 053 (63·1%) 36 257 (74·9%) 56 018 (68·8%)
Immigrant status, n (%) 1064 (1·5%) 20 125 (3·0%) 207 (0·4%) 438 (0·5%)
Lifetime individual mean disposable income, 1000 SEK (SD) 1041 (933) 1208 (1201) 1033 (1041) 1151 (1010)
Median age at diagnosis, years (IQR) 18·0 (7·9–31·5) ·· 16·1 (7·2–28·7) ··
Median age at death, years (IQR) 34·5 (21·0–44·0) 38·9 (27·9–46·7) 31·7 (17·7–41·9) 36·2 (24·8–44·8)
Data for single status were not available for 1527 individuals with epilepsy and 12 259 matched population controls, 910 patients with epilepsy with sibling controls, and 
301 unaﬀ ected sibling controls. Data for individual income were not available for 14 441 individuals with epilepsy, 139 580 matched population controls, 10 548 epilepsy 
patients with sibling controls, and 15 948 unaﬀ ected sibling controls. SEK=Swedish krona. IQR=interquartile range. 
Table 1: Baseline sociodemographic information for cohorts of individuals with epilepsy and comparison groups
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follow-up. Immigrant status was deﬁ ned as being born 
outside of Sweden. Missing data were not replaced by 
imputation or other methods. 
Any psychiatric, drug, and alcohol use disorders were 
deﬁ ned using inpatient (1969–2009) and outpatient 
(2001–09) primary or secondary diagnoses of any 
psychiatric condition (ICD-8: 290–315; ICD-9: 290–319; 
ICD-10: F00–F99), alcohol or drug use or dependence 
(ICD-8: 303, 304; ICD-9: 303, 304, 305.1, 305.9; ICD-10: 
F10–F19, except x.5), and depression and related mood 
disorders (ICD-8: 296, 298.0, 300.4; ICD-9: 296, 298A, 
300E, 311; ICD-10: F32–F39).
Analyses
For each patient, up to ten general population controls 
without any diagnosis of epilepsy were matched 
individually by birth year and sex (n=660 869). We esti-
mated the association between having been diagnosed 
with epilepsy and causes of death, as per related work 
using matched or sibling controls,20,23 using the clogit 
command in Stata, version 12 (StataCorp). The clogit 
command ﬁ ts conditional (ﬁ xed eﬀ ects) logistic regres-
sion models to matched case-control or cohort groups. 
We included three confounders (low income, single, and 
immigrant status) on theoretical grounds, based on 
related work in severe mental illness,20,27 and also tested 
whether they were each independently asso ciated with 
either case (epilepsy diagnosis) or con trol and outcome 
measures, respectively, in univariate analyses at the 5% 
level of signiﬁ cance.28 
Sibling control studies
To account for possible familial confounding, we did 
additional analyses that used unaﬀ ected full siblings of 
patients as controls. In this analysis, we identiﬁ ed as 
cases those individuals with epilepsy who also had full 
siblings without epilepsy, and these individuals were 
compared with their unaﬀ ected full siblings (n=81 396) 
using matched conditional logistic regression, and 
analyses were adjusted for age and sex.
Sensitivity analyses
We also did the following subanalyses. First, we investi-
gated categories of epilepsy and classiﬁ ed them into four 
types according to the diagnosis at ﬁ rst admission: 
complex partial seizures (ICD-8: 345.31; ICD-9: 345M, 
345N; ICD-10: G40.2), other partial seizures (ICD-8: 
345.30, 345.38, 345.39; ICD-10: G40.0, G40.1), generalised 
epilepsy (ICD-8: 345.00, 345.09, 345.10, 345.11; ICD-9: 
345J, 345K; ICD-10: G40.3), and other or unspeciﬁ ed 
epilepsy (ICD-8: 345.18, 345.19, 345.20, 345.29, 345.32, 
345.33, 345.9; ICD-9: 345L, 345P, 345Q, 345W, 345X; 
ICD-10: G40.4, G40.5, G40.6, G40.7, G40.8, G40.9, G41).23 
Second, based on International League Against Epilepsy 
recommendations of subclassifying epilepsy into clinical 
syndromes,29 we undertook a further sensitivity analysis 
based solely on ICD-10 codes, based on work using 
Danish national registers.30 Third, as an index of severity, 
we compared individuals whose ﬁ rst hos pital treatment 
episode lasted for 9 days or more (90th percentile) with 
the others (inpatients and out patients). Fourth, we 
investigated diﬀ erences by diagnostic threshold by com-
paring individuals with one or more diagnoses of 
epilepsy with those with two or more diagnoses. Fifth, we 
compared individuals with epilepsy by birth order. 
Finally, deaths by 10-year age-bands were investigated, 
and we also compared mortality risks in children who 
died under the age of 15 years with other ages. We 
followed STROBE guidelines (appendix).
Results
We identiﬁ ed 69 995 individuals with epilepsy and 
compared them with 660 869 age-matched and sex-
matched controls (table 1). Patients were followed up for 
an average of 9 years (interquartile range [IQR] 
5–18 years). Rates of psychiatric comorbidity were 18·0% 
before diagnosis of epilepsy and 22·7% after diagnosis, 
with high rates of depression and substance misuse 
(drug and alcohol use disorders; table 2).
6155 (8·8%) patients with epilepsy died before the end 
of the follow-up period compared with 4892 (0·7%) 
controls. We found a substantially elevated increased 
odds for all-cause mortality in individuals with epilepsy 
after matching for age and sex (odds ratio 14·1, 95% CI 
13·5–14·7), and after adjustment for sociodemographic 
confounders (adjusted odds ratio [aOR] 11·1, 95% CI 
10·6–11·6). In men, 3786 (10·2%) patients died during 
follow-up, compared with 3322 (1·0%) controls 
Patients, n (%) Controls, n (%)
Pre-existing diagnoses
Any psychiatric diagnosis 12 631 (18·0%) 23 067 (3·5%)
Substance misuse 4764 (6·8%) 6403 (1·0%)
Alcohol 3743 (5·3%) 4512 (0·7%)
Other substances 2449 (3·5%) 2933 (0·4%)
Depression 2377 (3·4%) 5390 (0·8%)
New diagnoses
Any psychiatric diagnosis 15 856 (22·7%) 45 314 (6·9%)
Substance misuse 3305 (4·7%) 12 543 (1·9%)
Alcohol 2496 (3·6%) 9008 (1·4%)
Other substances 2016 (2·9%) 5668 (0·9%)
Depression 3821 (5·5%) 16 523 (2·5%)
Lifetime diagnoses
Any psychiatric diagnosis 28 487 (40·7%) 68 381 (10·3%)
Substance misuse 8069 (11·5%) 18 946 (2·9%)
Alcohol 6239 (8·9%) 13 520 (2·0%)
Other substances 4465 (6·4%) 8601 (1·3%)
Depression 6198 (8·9%) 21 913 (3·3%)
Data are number (%) with psychiatric comorbidity. Any psychiatric disorder 
includes substance use diagnoses. New diagnoses refer to any psychiatric 
diagnoses made after ﬁ rst epilepsy diagnosis.
Table 2: Prevalence of pre-existing, new, and lifetime psychiatric 
morbidity in individuals with epilepsy
See Online for appendix
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(aOR 10·1, 95% CI 9·5–10·7); in women, 2369 (7·2%) 
patients died, compared with 1570 (0·5%) controls 
(13·0, 12·0–14·0). Adjusted odds ratios for ICD sub-
categories of mortality were mostly elevated (table 3), 
with most deaths in patients with diseases caused by the 
same underlying disease process as that leading to 
epilepsy. Of these, neoplasms (23·0% of deaths; 
aOR 11·2, 95% CI 10·3–12·2), and diseases of the 
nervous system (21·3% of deaths; 71, 57–88) were the two 
major causes. The next largest category was external 
causes (15·8% of deaths). The highest mortality odds 
ratio was for conditions originating in the perinatal 
period (1·6% of deaths; aOR 126, 95% CI 46–348).
The odds for external causes of death in individuals 
with epilepsy were also elevated (aOR 3·6, 95% CI 
3·3–4·0; table 4). For suicide (n=510), the adjusted odds 
ratio was 3·7 (95% CI 3·3–4·2). Deaths caused by non-
vehicle accidents (n=362) had the highest odds of death 
(aOR 5·5, 95% CI 4·7–6·5) among external causes 
(table 4). For death by assault (n=30), the adjusted odds 
ratio was 2·8 (95% CI 1·6–4·8). In further analyses of 
non-vehicle accidents, we found 135 deaths (37·3% of 
non-vehicle accidents) due to accidental drug poisoning, 
60 (16·6%) due to accidental falls, 55 (15·2%) drowning, 
and 112 (30·9%) other and unspeciﬁ ed accidental deaths.
We compared patients with epilepsy (n=48 437) with 
their unaﬀ ected siblings (n=81 396) for all-cause mor-
tality, natural causes, and speciﬁ c external causes. All 
risk estimates remained raised, including those for 
suicide (aOR 2·9, 95% CI 2·4–3·6) and non-vehicle 
accidents (6·3, 4·6–8·8; table 4). We found no evidence 
of familial confounding for non-vehicle accidents (since 
risk estimates were signiﬁ cant and of the same mag-
nitude as with the population controls). 
Diﬀ erences in mortality due to any external cause did 
not vary by severity and diagnostic thresholds in 
sensitivity analyses (table 5). Although odds of death by 
external causes were lower in those with two or more 
diagnoses of epilepsy, this diﬀ erence was not signiﬁ cant, 
and con ﬁ dence intervals overlapped. We found some 
evidence for diﬀ erences by epilepsy types in odds of 
external cause mortality. Special epilepsy syndromes 
(ICD-10 G40.5, including G40.5L epileptic encephalopathy 
with con tinuous spike-and-wave during sleep) had 
higher odds of non-vehicle accidents (aOR 24·2, 95% CI 
9·2–63·9) than other types of epilepsy (table 5). For 
suicide, women had higher odds of death (aOR 5·0, 
95% CI 4·0–6·3) than men (3·3, 2·8–3·8; interaction 
test p=0·002). After stratiﬁ cation by age groups, we 
found some evidence of higher odds ratios of external 
causes of mortality with increasing age. We found no 
diﬀ erences in odds or prevalence of mortality by birth 
order. Odds ratios of external causes were higher in the 
ﬁ rst 6 months after diagnosis of epilepsy (table 5). 
Sensitivity analyses for all natural causes of death, and 
speciﬁ cally for neoplasms and neurological causes, are 
shown in the appendix.
Odds ratio for death compared with 
population controls (aOR [95% CI])
Odds ratio for death compared 
with unaﬀ ected sibling controls 
(aOR [95% CI])
All-cause mortality 11·1 (10·6–11·6) 11·4 (10·4–12·5)
Natural causes 15·5 (14·6–16·4) 16·7 (14·9–18·7)
Neoplasms 11·2 (10·3–12·2) 11·3 (9·4–13·7)
Nervous system 71·1 (57·3–88·4) 86·9 (54·3–139·1)
External causes 3·6 (3·3–4·0) 3·2 (2·7–3·7)
Suicide 3·7 (3·3–4·2) 2·9 (2·4–3·6)
All accidents 3·6 (3·1–4·1) 3·6 (2·9–4·5)
Vehicle 1·4 (1·1–1·8) 1·5 (1·1–2·2)
Other 5·5 (4·7–6·5) 6·3 (4·6–8·8)
Drug poisoning 5·1 (3·9–6·5) 5·7 (3·3–9·7)
Fall 8·5 (5·3–13·7) 10·0 (2·9–33·8)
Drowning 7·7 (4·7–12·7) 9·5 (3·5–25·7)
Other and unspeciﬁ ed 4·9 (3·6–6·5) 5·2 (3·2–8·5)
Assault 2·8 (1·6–4·8) 1·7 (0·9–3·3)
Data are adjusted odds ratios (aOR) of external deaths compared with population controls (matched for age and sex, 
and adjusted for income, and marital and immigration status) or unaﬀ ected sibling controls (adjusted for age and sex). 
Table 4: Risks of premature death in individuals with epilepsy compared to population controls and 
unaﬀ ected siblings
Deaths in patients 
n (% of deaths)
Deaths in controls 
n (% of deaths)
Adjusted odds 
ratio (95% CI)
I Certain infectious and parasitic diseases 98 (1·6%) 68 (1·4%) 10·6 (7·3–15·4)
II Neoplasms 1416 (23·0%) 1146 (23·4%) 11·2 (10·3–12·2)
III Diseases of the blood and blood-forming 
organs and certain disorders involving the 
immune mechanism
19 (0·3%) 18 (0·4%) 15·3 (6·7–34·9)
IV Endocrine nutritional and metabolic 
diseases
277 (4·5%) 151 (3·1%) 14·2 (11·3–17·9)
V Mental and behavioural disorders 274 (4·5%) 122 (2·5%) 15·9 (12·1–20·8)
VI Diseases of the nervous system 1309 (21·3%) 124 (2·5%) 71·1 (57·3–88·4)
IX Diseases of the circulatory system 541 (8·8%) 655 (13·4%) 6·4 (5·6–7·3)
X Diseases of the respiratory system 281 (4·6%) 81 (1·7%) 21·2 (15·6–28·8)
XI Diseases of the digestive system 241 (3·9%) 149 (3·0%) 11·8 (9·3–14·9)
XIII Diseases of the musculoskeletal system 
and connective tissue
30 (0·5%) 19 (0·4%) 11·1 (5·5–22·4)
XIV Diseases of the genitourinary system 39 (0·6%) 15 (0·3%) 14·2 (7·0–28·7)
XVI Certain conditions originating in the 
perinatal period
96 (1·6%) 8 (0·2%) 126·3 (45·9–347·6)
XVII Congenital malformations, 
deformations, and chromosomal 
abnormalities
449 (7·3%) 94 (1·9%) 38·1 (27·7–52·5)
XVIII Symptoms, signs, and abnormal 
clinical and laboratory ﬁ ndings, not 
elsewhere classiﬁ ed
106 (1·7%) 134 (2·7%) 7·2 (5·3–9·8)
Other non-external (chapters VII, VIII, XII, 
XV, XIX)
7 (0·1%) 7 (0·2%) 12·7 (3·0–52·8)
XX External causes of morbidity and 
mortality
972 (15·8%) 2101 (42·9%) 3·6 (3·3–4·0)
Total deaths 6155 (100%) 4892 (100%) 11·1 (10·6–11·6)
Adjusted odds ratios refer to the odds of premature death by ICD chapter in patients with epilepsy compared with 
controls matched by sex and birth year, and adjusted by income, and immigrant and single status.
Table 3: Prevalence and odds of premature mortality in epilepsy, by International Classiﬁ cation of 
Diseases chapter
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There was an increased prevalence of psychiatric dis-
orders in epilepsy patients, and speciﬁ cally for alcohol and 
drug use disorders, and depression (table 2). By epilepsy 
syndrome, special syndromes had higher comorbid-
ity (81·3%) than unspeciﬁ ed (45·2%), focal (36·0%), 
generalised (29·6%) and other groups. Of those who died 
from external causes during follow-up, 75% (731 of 972; 
aOR 10·6, 95% CI 9·2–12·2) had a lifetime psychiatric 
diagnosis (including substance misuse) and, speciﬁ cally, 
549 (56%; 22·4, 18·3–27·3) had a history of substance 
External causes Suicide or uncertain Vehicle accidents Other accidents
n (% deaths) aOR (95% CI) n (% deaths) aOR (95% CI) n (% deaths) aOR (95% CI) n (% deaths) aOR (95% CI)
No epilepsy (n=660 869) 2101 (42·9%) 1·0 (ref) 1058 (21·6%) 1·0 (ref) 517 (10·6%) 1·0 (ref) 453 (9·3%) 1·0 (ref)
Epilepsy
Sex
Male (n=36 999) 711 (18·8%) 3·4 (3·1–3·8) 346 (9·1%) 3·3 (2·8–3·8) 74 (2·0%) 1·5 (1·1–2·0) 281 (7·4%) 5·2 (4·3–6·3)
Female (n=32 996) 261 (11·0%) 4·3 (3·6–5·1) 164 (6·9%) 5·0 (4·0–6·3) 17 (0·7%) 1·1 (0·6–2·1) 81 (3·4%) 7·2 (5·1–10·3)
Threshold
≥1 diagnosis (n=69 995) 972 (15·8%) 3·6 (3·3–4·0) 510 (8·3%) 3·7 (3·3–4·2) 91 (1·5%) 1·4 (1·1–1·8) 362 (5·9%) 5·5 (4·7–6·5)
≥2 diagnoses (n=48 105) 535 (12·9%) 3·1 (2·8–3·5) 257 (6·2%) 2·8 (2·4–3·4) 55 (1·3%) 1·5 (1·0–2·0) 218 (5·2%) 5·5 (4·5–6·8)
Severity
Less severe (n=62 143) 802 (17·4%) 3·6 (3·3–4·0) 428 (9·3%) 3·9 (3·4–4·4) 77 (1·7%) 1·6 (1·2–2·1) 293 (6·4%) 5·1 (4·2–6·0)
More severe (n=7852) 170 (11·0%) 3·4 (2·7–4·4) 82 (5·3%) 2·7 (1·9–3·8) 14 (0·9%) 0·8 (0·4–1·8) 69 (4·5%) 9·3 (6·0–14·5)
Source
Inpatient (n=50 071) 887 (15·2%) 3·7 (3·3–4·1) 459 (7·9%) 3·7 (3·2–4·2) 85 (1·5%) 1·5 (1·1–1·9) 334 (5·7%) 5·7 (4·8–6·8)
Outpatient only (n=19 924) 85 (25·3%) 3·1 (2·4–4·1) 51 (15·2%) 3·8 (2·7–5·4) 6 (1·8%) 1·0 (0·4–2·4) 28 (8·3%) 4·2 (2·6–7·0)
Type of seizures*
Complex partial (n=8382) 56 (13·0%) 2·2 (1·6–3·1) 31 (7·2%) 2·9 (1·8–4·5) 6 (1·4%) 1·2 (0·5–3·1) 20 (4·6%) 2·6 (1·4–4·8)
Other partial (n=5857) 55 (15·1%) 1·9 (1·3–2·8) 33 (9·0%) 1·9 (1·1–3·2) 8 (2·2%) 1·4 (0·6–3·3) 15 (4·1%) 3·1 (1·4–6·6)
Generalised (n=15 315) 179 (12·3%) 1·8 (1·5–2·3) 87 (6·0%) 1·8 (1·4–2·5) 20 (1·4%) 0·9 (0·5–1·6) 69 (4·7%) 3·1 (2·1–4·6)
Other and unspeciﬁ ed (n=40 441) 682 (17·5%) 5·1 (4·5–5·7) 359 (9·2%) 5·1 (4·4–6·0) 57 (1·5%) 1·7 (1·2–2·5) 258 (6·6%) 7·3 (6·0–8·9)
Type of epilepsy†
Focal (n=12 841) 55 (9·0%) 1·5 (1·1–2·1) 31 (5·1%) 2·0 (1·3–3·0) 7 (1·1%) 0·7 (0·3–1·7) 19 (3·1%) 2·0 (1·1–3·6)
Generalised (n=7593) 24 (14·1%) 1·4 (0·9–2·3) 12 (7·1%) 1·8 (0·9–3·5) 3 (1·8%) 0·5 (0·2–1·8) 9 (5·3%) 2·6 (1·1–6·0)
Encephalopathy and mixed (n=1894) 10 (4·9%) 2·5 (1·2–5·5) 7 (3·4%) 4·1 (1·5–10·8) 1 (0·5%) 1·0 (0·1–8·8) 2 (1·0%) 1·8 (0·3–9·9)
Special syndromes (n=894) 39 (26·4%) 9·5 (5·3–17·0) 16 (10·8%) 4·3 (2·0–9·3) 1 (0·7%) 2·7 (0·2–31·2) 22 (14·9%) 24·2 (9·2–63·9)
Other epilepsy (n=710) 8 (14·8%) 5·4 (2·1–14·4) 0 (0·0%) ·· 1 (1·9%) 1·8 (0·1–24·2) 7 (13·0%) 12·8 (3·9–42·6)
Unspeciﬁ ed epilepsy (n=29 997) 352 (16·1%) 4·8 (4·1–5·5) 173 (7·9%) 4·3 (3·5–5·3) 31 (1·4%) 2·3 (1·5–3·6) 139 (6·3%) 6·9 (5·4–8·8)
Age at death
0–15 (n=69 995) 45 (4·0%) 3·8 (1·9–7·6) 7 (0·6%) 4·7 (1·0–22·2) 5 (0·4%) ·· 27 (2·4%) 5·1 (2·2–11·6)
16–25 (n=68 877) 135 (14·8%) 1·8 (1·3–2·3) 67 (7·3%) 1·9 (1·3–2·8) 20 (2·2%) 0·8 (0·4–1·5) 40 (4·4%) 3·4 (2·0–5·6)
26–35 (n=67 963) 276 (21·8%) 3·3 (2·8–4·0) 157 (12·4%) 3·3 (2·6–4·3) 28 (2·2%) 1·7 (1·1–2·8) 95 (7·5%) 5·3 (3·7–7·4)
36–45 (n=66 691) 338 (20·7%) 4·9 (4·2–5·7) 189 (11·6%) 5·1 (4·2–6·3) 20 (1·2%) 1·6 (0·9–2·6) 135 (8·3%) 7·0 (5·4–9·1)
46–56 (n=65 055) 178 (14·6%) 5·7 (4·7–7·0) 90 (7·4%) 5·5 (4·2–7·3) 18 (1·5%) 6·3 (3·3–12·0) 65 (5·3%) 6·3 (4·4–9·0)
Birth order
Firstborn (n=21 131) 263 (14·3%) 3·1 (2·7–3·7) 129 (7·0%) 3·2 (2·5–4·1) 28 (1·5%) 1·2 (0·8–2·0) 107 (5·8%) 5·2 (3·8–7·0)
Not ﬁ rstborn (n=27 306) 314 (15·3%) 3·6 (3·1–4·2) 169 (8·2%) 4·0 (3·2–4·9) 36 (1·8%) 1·6 (1·0–2·4) 102 (5·0%) 4·7 (3·5–6·2)
No siblings (n=21 558) 395 (17·4%) 4·0 (3·4–4·7) 212 (9·4%) 3·7 (3·0–4·6) 27 (1·2%) 1·4 (0·9–2·4) 153 (6·8%) 6·6 (5·1–8·7)
Time period
0–182 days (n=69 995) 97 (10·8%) 13·8 (9·2–20·9) 50 (5·6%) 17·9 (9·8–32·6) 7 (0·8%) 3·6 (1·0–12·5) 39 (4·4%) 23·5 (10·3–53·4)
183–365 days (n=69 096) 58 (11·5%) 8·3 (5·3–12·9) 36 (7·1%) 13·0 (6·9–24·3) 6 (1·2%) 2·1 (0·6–7·1) 15 (3·0%) 10·6 (4·0–28·1)
≥366 days (n=68 592) 817 (17·2%) 3·3 (3·0–3·6) 424 (8·9%) 3·3 (2·9–3·8) 78 (1·6%) 1·4 (1·0–1·8) 308 (6·5%) 5·2 (4·4–6·2)
% deaths refers to proportion of all deaths for row category which were due to the column cause (eg, of the male deaths in epilepsy, 18·8% were from external causes). Adjusted odds ratios (aOR) report odds of 
mortality in individuals with epilepsy compared with general population controls (matched for age and sex, and adjusted for income, and marital and immigration statuses). Suicide category includes 
undetermined deaths.*Complex partial (ICD-8: 345.31; ICD-9: 345M, 345N; ICD-10: G40.2); other partial (ICD-8: 345.30, 345.38, 345.39; ICD-10: G40.0, G40.1); generalised (ICD-8: 345.00, 345.09, 345.10, 
345.11; ICD-9: 345J, 345K; ICD-10: G40.3); other and unspeciﬁ ed (ICD-8: 345.18, 345.19, 345.20, 345.29, 345.32, 345.33, 345.9; ICD-9: 345L, 345P, 345Q, 345W, 345X; ICD-10: G40.4, G40.5, G40.6, G40.7, 
G40.8, G40.9, G41). †Focal (ICD-10: G40.0, G40.1, G40.2); generalised (ICD-10: G40.3); encephalopathy and mixed (ICD-10: G40.4); special syndromes (ICD-10: G40.5); other epilepsy (ICD-10: G40.8); 
unspeciﬁ ed epilepsy (ICD-10: G40.6, G40.7, G40.9).
Table 5: Mortality risks after diagnosis with epilepsy, stratiﬁ ed by diagnostic threshold, sex, severity, patient type, epilepsy subtype, age group, birth order, and time after ﬁ rst diagnosis
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misuse, and 227 (23%; aOR 13·0, 95% CI 10·3–16·6) had 
depression (table 6). We found no diﬀ erences in odds of 
mortality between psychiatric disorders diagnosed before 
epilepsy and those diagnosed after (data not shown). In 
those with psychiatric comorbidity, we found evidence 
for an association between epilepsy and external cause 
mortality (aOR 2·3, 95% CI 1·9–2·8), suicide (2·1, 
1·5–2·9), vehicle accidents (1·9, 1·3–2·6), and non-vehicle 
accidents (aOR 3·5, 2·5–4·9). In addition, we looked at all 
natural causes of death, and the two most common causes 
(neoplasms, neurological) and did not ﬁ nd strong asso-
ciations with psychiatric comorbidity (appendix). 
Discussion
Our results indicate high rates of premature mortality in 
epilepsy, and highlight the substantial contribution of 
psychiatric comorbidity to this mortality. The ﬁ ndings 
potentially contribute to the clinical management of 
epilepsy for neurology, psychiatry, and primary care 
services by presenting information on associations with 
treatable psychiatric disorders. To our knowledge, this is 
the ﬁ rst time that unaﬀ ected sibling controls have been 
used to assess mortality in epilepsy (panel). 
We report three main ﬁ ndings. First, the adjusted odds 
of all-cause mortality, which followed individuals with 
epilepsy until they were 56 years old, was 11 compared 
with both general population and unaﬀ ected sibling 
controls. 16% of all epilepsy deaths were from external 
causes, which was the largest category of deaths that was 
not clearly related to underlying disease processes (such 
as brain tumours and infections). A notable ﬁ nding was 
the high risk of death from non-vehicle accidents, with 
adjusted odds of death at 5·5 (95% CI 4·7–6·5). Second, 
we found evidence that epilepsy is an independent risk 
factor for all-cause and external causes of death. This was 
most clearly shown when we compared patients with 
their unaﬀ ected siblings. For external causes, the odds of 
mortality in people with epilepsy were increased at 
2·9 for suicide and 3·6 for accidents compared with 
unaﬀ ected siblings. 
The independent eﬀ ect of epilepsy on suicide contrasts 
with some previous research,7,8 but supports another 
population study,6 which found an independent eﬀ ect of 
epilepsy on external causes of death. We believe our 
ﬁ ndings are robust, since our study beneﬁ ted from a large 
sample size, various sensitivity analyses, and examined 
familial confounding. Third, patients with epi lepsy 
and psychiatric comorbidity have very high mor tality. 
Speciﬁ cally, individuals with epilepsy and comorbid 
depression had an odds ratio for suicide of 23 compared 
External causes Suicide or uncertain Vehicle accidents Other accidents
n (%) aOR (95% CI) n (%) aOR (95% CI) n (%) aOR (95% CI) n (%) aOR (95% CI)
Any psychiatric disorder
No epilepsy, no 
psychiatric disorder
1230 (0·2%) 1·0 (ref) 488 (0·1%) 1·0 (ref) 452 (0·1%) 1·0 (ref) 234 (0·1%) 1·0 (ref)
No epilepsy, psychiatric 
disorder
871 (1·3%) 5·8 (5·2–6·6) 570 (0·8%) 9·3 (7·8–11·0) 65 (0·1%) 1·0 (0·7–1·4) 219 (0·3%) 7·5 (5·9–9·6)
Epilepsy, no psychiatric 
disorder
241 (0·6%) 2·3 (1·9–2·8) 81 (0·2%) 2·1 (1·5–2·9) 61 (0·1%) 1·9 (1·3–2·6) 91 (0·2%) 3·5 (2·5–4·9)
Epilepsy, psychiatric 
disorder
731 (2·6%) 10·6 (9·2–12·2) 429 (1·5%) 14·0 (11·5–17·0) 30 (0·1%) 0·9 (0·6–1·5) 271 (1·0%) 23·3 (17·4–31·3)
Depression
No epilepsy, no 
depression
1790 (0·3%) 1·0 (ref) 809 (0·1%) 1·0 (ref) 500 (0·1%) 1·0 (ref) 411 (0·1%) 1·0 (ref)
No epilepsy, depression 311 (1·4%) 5·1 (4·3–6·1) 249 (1·1%) 9·9 (7·9–12·4) 17 (0·1%) 1·1 (0·6–1·9) 42 (0·2%) 2·3 (1·5–3·4)
Epilepsy, no depression 745 (1·2%) 3·3 (3·0–3·7) 328 (0·5%) 3·1 (2·6–3·6) 86 (0·1%) 1·4 (1·1–1·9) 316 (0·5%) 5·5 (4·6–6·6)
Epilepsy, depression 227 (3·7%) 13·0 (10·3–16·6) 182 (2·9%) 22·9 (16·6–31·6) 5 (0·1%) 1·1 (0·4–2·9) 46 (0·7%) 9·9 (6·1–16·1)
Substance misuse
No epilepsy, no 
substance misuse
1562 (0·2%) 1·0 (ref) 759 (0·1%) 1·0 (ref) 477 (0·1%) 1·0 (ref) 263 (0·1%) 1·0 (ref)
No epilepsy, substance 
misuse
539 (2·8%) 8·6 (7·4–10·0) 299 (1·6%) 9·4 (7·6–11·6) 40 (0·2%) 1·7 (1·1–2·5) 190 (1·0%) 20·0 (14·3–27·9)
Epilepsy, no substance 
misuse
423 (0·7%) 2·2 (1·9–2·6) 191 (0·3%) 2·2 (1·8–2·6) 68 (0·1%) 1·2 (0·9–1·7) 151 (0·2%) 4·2 (3·2–5·4)
Epilepsy, substance 
misuse
549 (6·8%) 22·4 (18·3–27·3) 319 (4·0%) 21·5 (16·6–27·8) 23 (0·3%) 3·1 (1·7–5·5) 211 (2·6%) 43·3 (28·8–65·1)
Number of deaths in epilepsy and associated controls, stratiﬁ ed by psychiatric diagnoses. % is percentage of deaths from a particular cause within the row sample (eg, of 
those with no epilepsy and no psychiatric disorder, 0·2% died from external causes). Adjusted odds ratios (aOR) report odds of morality compared with the reference group. 
Suicide category includes undetermined deaths. 
Table 6: Associations of external causes of death in epilepsy with psychiatric comorbidity
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with non-depressed general population controls, and those 
with epilepsy and comorbid substance misuse of 21. The 
corresponding odds of suicide in general popu lation 
controls with depression but without epilepsy was 10. For 
deaths from non-vehicle accidents, there was a strong 
association with substance misuse (as suggested by an 
increase in odds of mortality of 43 in epilepsy and comorbid 
substance misuse, compared with 20 in general population 
controls without epilepsy but with sub stance misuse).
The high odds associated with congenital conditions 
and those arising in the perinatal period, such as cerebral 
palsy, is not surprising, since these underlying conditions 
are associated with the most severe forms of epilepsy. This 
mortality risk underlines the importance of preventing 
these causes of death during the perinatal period and 
perhaps the need to examine interventions to prevent 
epileptogenesis in those exposed to perinatal events.
Our ﬁ nding of an 11-fold increase in odds of all-cause 
mortality compared with general population controls is 
higher than that reported in some other mortality studies, 
but consistent with the few studies that have examined 
premature mortality. For example, one population study 
in Sweden found standardised mortality ratios between 
10 and 14 in hospitalised patients aged 15–54 years.4 
Furthermore, we reported an increased odds of suicide of 
3·7 that is within the range reported in a recent 
systematic review.5 Although a few population based 
studies have presented data for psychiatric comorbidity, 
estimates in our study are within the range of 19–48% 
reported in a review article,31 and consistent with the 36% 
found in a community survey of patients with epilepsy.32 
Additionally, our prevalence of depression of 8·9% is 
similar to the 9·6% found in a recent study of 
7403 individuals with epilepsy in England.33
Our ﬁ ndings suggest that risks for external causes of 
death, and potential treatments to mitigate these risks, 
need to be considered in patients with epilepsy. The 
importance of identifying, monitoring, and treating 
psychiatric comorbidity, discussed recently in an expert 
review,34 is underscored by these results. This was most 
clearly shown in our ﬁ nding that around three-quarters 
of deaths from external causes in the epilepsy cohort 
were in patients who had a lifetime psychiatric diagnosis. 
In particular, patients with psychiatric comorbidity in the 
period immediately after the ﬁ rst diagnosis of epilepsy 
represent a high-risk population that might beneﬁ t from 
closer monitoring, consultation with liaison psychiatry, 
and more intensive treatments. But our results also 
highlight the role of other risk factors beyond psychiatric 
comorbidity as suicide and accident deaths were in-
creased in those without lifetime co-occurring psych-
iatric disorders. Such risk factors may include more 
sensitive measures of disease course and severity than 
we were able to investigate, treatment-related factors,5 
and direct eﬀ ects of the condition on decision making in 
some people.35 Additionally, the importance of other 
causes of death is also underlined by our ﬁ ndings; 
neurological causes had the highest rates and risks, and 
the contribution of sudden unexplained deaths needs 
further examination.36 
Moreover, our ﬁ ndings highlight the importance of 
non-vehicle accidents as a major preventable cause of 
death in people with epilepsy. One possible implication 
is whether speciﬁ c warnings and patient education, 
besides those already given, should be provided to 
patients about risks of non-vehicle accidents, including 
their link to substance misuse.
Although the relative risks were high, absolute rates of 
premature mortality from external causes were 1·4%, 
and any changes to clinical practice need to consider how 
to identify high-risk populations with low false positive 
rates. Nevertheless, as we found around a third of 
epilepsy patients had a comorbid psychiatric diagnosis, 
and around a tenth had comorbid substance misuse, 
clinical epilepsy services could review their liaison with 
psychiatric37 and addiction services. The importance of 
substance misuse in suicide mortality was at least as 
important as depression, but it has not been highlighted 
in recent reviews.34 Previous work has examined the role 
of alcohol comorbidity in suicide risk,6 but little is known 
about comorbid drug use. 
There are two main limitations in this study. The ﬁ rst is 
that we restricted our cohort to those born between 1954 
and 2009. This was done to focus on premature mortality 
and so that our ﬁ ndings would not be potentially diluted 
by the large mortality eﬀ ects of older people. This 
restriction also avoided cohort eﬀ ects with older people, 
for whom services and treatments were considerably 
diﬀ erent before 1970. Nevertheless, results are conﬁ ned 
to premature deaths. A second limitation is that we used 
patient registers to identify people with epilepsy, since it 
Panel: Research in context
Systematic review
We searched Medline for articles comparing mortality in epilepsy to general population 
controls and examining the role of psychiatric comorbidity, published up to March 29, 
2013, with no language or date restrictions, and with the search terms “epilepsy” and 
(“mortality” or “death”) and “psych*”. We also scanned references of key articles. 
We identiﬁ ed two population-based case-control studies. A Danish study6 
(n=492 suicides) found epilepsy to be a risk factor for suicide independent of increased 
risk of psychiatric comorbidity. A Canadian study7 (n=203 fatal and non-fatal accidents, 
suicide and suicide attempts, and self-inﬂ icted injuries), however, found no increased risk 
of external causes of death in epilepsy after adjusting for comorbidity. 
Interpretation
Our study substantially increases the evidence on the contribution of psychiatric morbidity 
to mortality in epilepsy. Additionally, for the ﬁ rst time, we examine odds of premature 
death in individuals with epilepsy compared with their unaﬀ ected siblings, and ﬁ nd that 
they do not diﬀ er signiﬁ cantly from mortality odds in epilepsy compared with general 
population controls. This strongly suggests that epilepsy is an independent risk factor for 
all-cause and external cause mortality. External causes of death were strongly associated 
with psychiatric conditions, and we conclude that premature mortality in epilepsy might be 
reduced with improved identiﬁ cation and treatment of these comorbidities. 
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was necessary to use routinely collected data to provide 
precision for the fairly rare outcomes investigated. 
Syndromal approaches are now recommended to 
subclassify epilepsy29 and translating ICD codes into 
these syndromes might be subject to some mis-
classiﬁ cation.30 Nevertheless, using either ICD codes or 
syndromes, epilepsies that were not focal or generalised 
(and described variously as other or special epileptic 
syndromes) could incur higher risk of premature 
mortality. We used both outpatient and inpatient data to 
identify cases, and found no obvious diﬀ erences in 
mortality. However, we might be missing a proportion 
of patients who never present to secondary services, 
although we estimate that this number would be small 
for a chronic illness such as epilepsy in a country with 
a comprehensive tax-funded health system such as 
Sweden, and over an average follow-up of 9 years. This 
small missing proportion is likely due to the long-
standing practice for ﬁ rst diagnoses of epilepsy to be 
conﬁ rmed by specialist services.38 Nevertheless, under-
sampling of patients with less severe symptoms could 
lead to an over estimation of the association with pre-
mature death if individuals with less severe disease are 
both less likely to be diagnosed and have fewer co-
morbidities and mortality risks.
We also only studied one country, and the general-
isability to other countries is uncertain. An estimate of 
the prevalence of epilepsy based on our sample is 
diﬃ  cult, since the 41 year cohort does not lend itself to 
such a calculation. However, when extrapolating the 
prevalence reported in this cohort to a lifetime prevalence, 
we ﬁ nd a similar prevalence estimate to that reported in 
other high-income countries.2 Sweden is not dissimilar 
to other western European countries in suicide rates39 but 
comparative information on death by accidents is limited. 
Finally, some of the causes of death may be prone to 
misclassiﬁ cation. Suicide and deaths from undetermined 
causes were combined to account for this, but it is 
possible that some accidental deaths are in fact suicides.40
Some accidental deaths will also be a direct con-
sequence of seizures, and therefore the associations 
with substance misuse might not be causal. Treatment 
trials in this population are necessary to determine the 
precise role of substance misuse and other psychiatric 
disorders on premature death. We were also unable to 
examine the eﬀ ect of psychiatric comorbidity on sudden 
unexpected deaths in epilepsy which contribute to 
around 4% of deaths in community samples,41 and are 
deﬁ ned as death due to sudden and unexplained 
respiratory failure or cardiac arrest.36 Future research 
should examine the relation between epilepsy, psych-
iatric comorbidity, and prescribed medication (par-
ticularly selective serotonin reuptake inhibitors)42 on 
sudden unexpected deaths. However, we did examine 
the association of psychiatric morbidity with two main 
causes of natural deaths, namely cancer and neurological 
diseases (appendix). We did not ﬁ nd strong associations 
with psychiatric comorbidity, which was not surprising 
since these underlying causes of epilepsy are likely to 
cause death directly.
We found no evidence of familial confounding in all-
cause and external mortality, a somewhat unexpected 
ﬁ nding, as previous studies have suggested that familial 
(genetic or early environmental) eﬀ ects explain a 
substantial part of the association between epilepsy and 
violent crime.23 However, it strengthens the hypothesis 
that epilepsy is on the causal pathway to premature death.
In summary, psychiatric comorbidity has an import-
ant role in the premature mortality seen in epilepsy. 
Reducing premature mortality from external causes of 
death should be a priority in epilepsy management. 
The ability of health services to prevent such deaths 
requires review. 
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